Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.